DRS

The Progeria Research Foundation Selected as an Official Charity Partner in 2024 Boston Marathon

Retrieved on: 
Tuesday, March 26, 2024
Research, Friends, Disease, Emmy Awards, Memory, Partnership, TED, Boston Athletic Association, PRF, Bank, Attitude, Progeria Research Foundation, Athlete, Boston Marathon, Thought, DRS, HBO, FDA, TED (conference), Parent, Boston, Boylston Street

PEABODY, Mass., March 26, 2024 /PRNewswire/ -- The Progeria Research Foundation (PRF), the only nonprofit solely dedicated to finding treatments and the cure for Progeria, celebrates its first year as an Official Charity Partner of the Boston Athletic Association's 128th Bank of America Boston Marathon®. Represented by a team of 10 passionate runners, this partnership will bring vital funds for Progeria research endeavors, while casting a light on this ultra-rare disease and PRF's progress toward the cure.

Key Points: 
  • PRF's 10 Marathon Runners Raise Funds to cure Progeria, all connected to Sam Berns
    PEABODY, Mass., March 26, 2024 /PRNewswire/ -- The Progeria Research Foundation (PRF), the only nonprofit solely dedicated to finding treatments and the cure for Progeria, celebrates its first year as an Official Charity Partner of the Boston Athletic Association's 128th Bank of America Boston Marathon®.
  • Without treatment, children with Progeria die of heart disease at an average age of 14.5 years old.
  • "From Foxboro neighbors, to middle school classmates, to athletes who got to know Sam at PRF's annual 5K Race for Research – it's heartwarming to know they're now representing The Progeria Research Foundation at the Boston Marathon, in Sam's honor."
  • "This is a tremendous honor to be invited to join the Bank of America's Official Charity Program in the 2024 Boston Marathon," said Audrey Gordon, President and Executive Director of The Progeria Research Foundation.

Debbie's Dream Foundation: Curing Stomach Cancer Announce Groundbreaking Research Fellowship Grant for Gastric Cancer Research

Retrieved on: 
Tuesday, March 19, 2024
Partnership, Education, Patient, Biomarker, Research, Helicobacter pylori, AACR, DRS, DDF, Stomach, MSK, Gastrointestinal cancer, Health, Stomach cancer, Pharmaceutical industry

FORT LAUDERDALE, Fla., March 19, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) announces an unprecedented collaboration with Memorial Sloan Kettering Cancer Center (MSK) that marks a significant leap forward in the field of gastric cancer research. Through the visionary efforts and support of DDF, a research fellowship grant has been established at MSK under the guidance of Dr. Yelena Janjigian, Chief of Gastrointestinal Oncology Service at MSK. The "Debbie's Dream Foundation Gastric Cancer Investigator" fellowship will focus on patient care, research, and education specifically for esophageal and gastric cancers. The collaboration is a testament to the shared commitment of DDF and MSK to fueling groundbreaking research and providing top-notch cancer care.

Key Points: 
  • FORT LAUDERDALE, Fla., March 19, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) announces an unprecedented collaboration with Memorial Sloan Kettering Cancer Center (MSK) that marks a significant leap forward in the field of gastric cancer research.
  • The "Debbie's Dream Foundation Gastric Cancer Investigator" fellowship will focus on patient care, research, and education specifically for esophageal and gastric cancers.
  • The collaboration is a testament to the shared commitment of DDF and MSK to fueling groundbreaking research and providing top-notch cancer care.
  • Through the 'Debbie's Dream Foundation Gastric Cancer Investigator fellowship, we aim to make impactful strides in biomarker development, laboratory research, and translational studies in gastroesophageal cancer."

Acclaimed Clinical Geneticist Dr. Bruce Korf Honored with 2024 David L. Rimoin Lifetime Achievement Award in Medical Genetics from the ACMG Foundation for Genetic and Genomic Medicine

Retrieved on: 
Wednesday, March 13, 2024
Department of Defence, Friends, Patient, Medical genetics, Travel, Child, Neurofibromatosis, Practice, UAB, Gene expression, Dean (education), Education, Rockefeller University, Seed, NF, NIH, American College, Pediatrics, Person, Karyotype, MD–PhD, Boston Children's Hospital, Principle, Birmingham School of Law, Neurology, FACOG, Genetics, Cornell University, American Journal, Research, Hospital, University, Human genetics, Student, Publication, DRS, ACMG, Book, Genetic distance, DSM-IV codes, Diagnosis, FACMG, Empathy, Montefiore Medical Center, Distinguishing, Mouse, Hope, Doctor of Philosophy, Life, Genetic, Bangladesh Technical Education Board, Physician, Nursing

BETHESDA, Md., March 13, 2024 /PRNewswire/ -- Renowned clinical geneticist Bruce Korf, MD, PhD, FACMG, has been named the recipient of the 2024 ACMG Foundation for Genetic and Genomic Medicine's David L. Rimoin Lifetime Achievement Award in Medical Genetics.

Key Points: 
  • BETHESDA, Md., March 13, 2024 /PRNewswire/ -- Renowned clinical geneticist Bruce Korf, MD, PhD, FACMG, has been named the recipient of the 2024 ACMG Foundation for Genetic and Genomic Medicine's David L. Rimoin Lifetime Achievement Award in Medical Genetics.
  • Dr. Korf is an authentic, kind and ethical human being whose life and career in medical genetics are unparalleled."
  • "Dr. Korf's extraordinary accomplishments in clinical genetics, neurofibromatosis, and genomics, as well as his dedication to education make him a well deserving winner of the David Rimoin Lifetime Achievement Award.
  • Before he died, David appreciated the opportunity to work with Bruce first-hand in the editing of Principles and Practice of Medical Genetics as well as on numerous committees for the ACMG.

Clario and Cleveland Clinic's Cole Eye Institute announce strategic partnership to provide new ophthalmology offerings for clinical trials

Retrieved on: 
Tuesday, March 12, 2024
Prevalence, Kaiser, Multiple sclerosis, Alzheimer's disease, Partnership, Patient, Eye, Cleveland Clinic, Clinical trial, DRS, Fluorescein angiography, Therapy, Diabetic retinopathy, Ophthalmology, Medical imaging

PHILADELPHIA, Pa., March 12, 2024 /PRNewswire/ -- Clario, a healthcare research and technology company that delivers the leading endpoint technology solutions for clinical trials, today announced a strategic partnership with the Cleveland Clinic's renowned Cole Eye Institute. The partnership brings Cleveland Clinic's ophthalmology imaging expertise and AI-driven analysis platforms together with Clario's industry-leading vendor-agnostic image management system. The collaboration will support clinical trials evaluating the efficacy of therapeutics designed to treat the eye as well as other trials monitoring ophthalmic safety events.

Key Points: 
  • Strategic partnership helps sponsors overcome common clinical trial challenges and drive critical ophthalmic advances in treatment for patients.
  • PHILADELPHIA, Pa., March 12, 2024 /PRNewswire/ -- Clario , a healthcare research and technology company that delivers the leading endpoint technology solutions for clinical trials, today announced a strategic partnership with the Cleveland Clinic's renowned Cole Eye Institute.
  • The partnership brings Cleveland Clinic's ophthalmology imaging expertise and AI-driven analysis platforms together with Clario's industry-leading vendor-agnostic image management system.
  • To learn more about Clario and its broad range of solutions offerings for the ophthalmology therapeutic area, please visit https://clario.com/therapeutic-areas/ophthalmology/ .

Clario and Cleveland Clinic's Cole Eye Institute announce strategic partnership to provide new ophthalmology offerings for clinical trials

Retrieved on: 
Tuesday, March 12, 2024
Prevalence, Kaiser, Multiple sclerosis, Alzheimer's disease, Partnership, Patient, Eye, Cleveland Clinic, Clinical trial, DRS, Fluorescein angiography, Therapy, Diabetic retinopathy, Ophthalmology, Medical imaging

PHILADELPHIA, Pa., March 12, 2024 /PRNewswire/ -- Clario, a healthcare research and technology company that delivers the leading endpoint technology solutions for clinical trials, today announced a strategic partnership with the Cleveland Clinic's renowned Cole Eye Institute. The partnership brings Cleveland Clinic's ophthalmology imaging expertise and AI-driven analysis platforms together with Clario's industry-leading vendor-agnostic image management system. The collaboration will support clinical trials evaluating the efficacy of therapeutics designed to treat the eye as well as other trials monitoring ophthalmic safety events.

Key Points: 
  • Strategic partnership helps sponsors overcome common clinical trial challenges and drive critical ophthalmic advances in treatment for patients.
  • PHILADELPHIA, Pa., March 12, 2024 /PRNewswire/ -- Clario , a healthcare research and technology company that delivers the leading endpoint technology solutions for clinical trials, today announced a strategic partnership with the Cleveland Clinic's renowned Cole Eye Institute.
  • The partnership brings Cleveland Clinic's ophthalmology imaging expertise and AI-driven analysis platforms together with Clario's industry-leading vendor-agnostic image management system.
  • To learn more about Clario and its broad range of solutions offerings for the ophthalmology therapeutic area, please visit https://clario.com/therapeutic-areas/ophthalmology/ .

World Brain Mapping Foundation (WBMF) announced its 2024 award recipients holding its 21st Gathering for Cure (GFC) Awards Gala at the Historic Millenium Biltmore hotel in LA.

Retrieved on: 
Tuesday, March 12, 2024
Karma, Research, Brain mapping, Culture, Brain technology, Innovation Park, Taste, Veteran, WBMF, Doe, Patient, Millennium Biltmore Hotel, Alzheimer's disease, Neuroscience, Disease, Associate, Journal, Loma Linda University, GFC, Health, Pioneer, Michelson Medical Research Foundation, Journal of Alzheimer's Disease, NASA, Neuroelectrics, DSM-IV codes, Therapy, DRS, Springer Nature, State, Neurosurgery, Pharmaceutical industry

LOS ANGELES, March 11, 2024 /PRNewswire/ -- The World Brain Mapping Foundation (WBMF) announced its 2024 award recipients and will hold the 21st Gathering for Cure (GFC) Awards Gala on Friday March 15, 2024 at former home to the Oscars, Millennium Biltmore Hotel in Los Angeles.

Key Points: 
  • LOS ANGELES, March 11, 2024 /PRNewswire/ -- The World Brain Mapping Foundation (WBMF) announced its 2024 award recipients and will hold the 21st Gathering for Cure (GFC) Awards Gala on Friday March 15, 2024 at former home to the Oscars, Millennium Biltmore Hotel in Los Angeles.
  • Joe Bolanos, Kevin Morris, George Perry, Dave Baron, and Ms. Ira Soebroto-Bullo (Golden Axon Leadership award) and Aysha Noor and Jemma Yoo (Student Service, Research and Leadership Award).
  • "Our award recipients are truly pioneers in their fields who have impacted millions of patients globally", said Dr. Babak Kateb, President of WBMF.
  • "GFC award is also aimed at raising funds for introducing new diagnostics and therapeutics for neurological disorders."

EQS-News: Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Retrieved on: 
Wednesday, March 13, 2024
Senior, Biotechnology, NPV, PMA, Messenger, Next Generation, FDA, Partnership, PPV, Marketing, Food, CRC, AA, Biomarker, Science, Quest Diagnostics, THA, Patient, Clinical trial, Survival, DRS, Colorectal cancer, Gene expression

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Key Points: 
  • Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
    The issuer is solely responsible for the content of this announcement.
  • Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
    Dr. Jay Wohlgemuth, former Chief Medical & Scientific Officer of Quest Diagnostics and Dr. Ray Tabibiazar, a seasoned industry executive, to lead collaboration
    BERKELEY, US – MAINZ, Germany – March 5, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today a partnership with Trusted Health Advisors (THA), a market leader in supporting the U.S. launches and management of commercial programs for diagnostic products.
  • In the U.S., Mainz Biomed is in final regulatory planning stages of ReconAAsense clinical trial to seek Premarket Approval (PMA) for its next generation diagnostic test.
  • The Company currently commercializes its first-generation test in Europe and in select international territories through its flagship product ColoAlert® via partnerships with third-party laboratories.

ATHA Energy and Latitude Uranium Complete Merger Creating a Leading Uranium Explorer

Retrieved on: 
Thursday, March 7, 2024
Odyssey, Acquisition, Arrangement, Telephone, News, FRA, Growth, Letter, Mergers and acquisitions, LUR, Uranium, DRS, Athabasca Basin, Trust, Security (finance)

VANCOUVER, British Columbia and TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- ATHA Energy Corp. (TSXV: SASK) (FRA: X5U) (OTCQB: SASKF) (“ATHA”) and Latitude Uranium Inc. (CSE: LUR) (OTCQB: LURAF) (FRA: EI1) (“Latitude Uranium”) are pleased to announce the successful completion of the previously announced arrangement (the “Arrangement” or the “Merger”) whereby ATHA has acquired 100% of the issued and outstanding common shares of Latitude Uranium (the “LUR Shares”) and Latitude Uranium has become a wholly owned subsidiary of ATHA.

Key Points: 
  • VANCOUVER, British Columbia and TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- ATHA Energy Corp. (TSXV: SASK) (FRA: X5U) (OTCQB: SASKF) (“ATHA”) and Latitude Uranium Inc. (CSE: LUR) (OTCQB: LURAF) (FRA: EI1) (“Latitude Uranium”) are pleased to announce the successful completion of the previously announced arrangement (the “Arrangement” or the “Merger”) whereby ATHA has acquired 100% of the issued and outstanding common shares of Latitude Uranium (the “LUR Shares”) and Latitude Uranium has become a wholly owned subsidiary of ATHA.
  • Pursuant to the Arrangement, Latitude Uranium shareholders (the “LUR Shareholders”) received 0.2769 common shares of ATHA (each whole share, an “ATHA Share”) for each LUR Share held.
  • ATHA will cause Latitude Uranium to apply to the relevant Canadian securities regulatory authorities to cease to be a reporting issuer under applicable Canadian securities laws.
  • Full details of the Merger and certain other matters are set out in the management information circular of Latitude Uranium and can be found under Latitude Uranium’s issuer profile on SEDAR+ at www.sedarplus.ca .

Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Including Live Product Showcase Featuring the Company’s New Stratys™ System

Retrieved on: 
Thursday, March 7, 2024
SAN, Medical college, Medical College of Wisconsin, Vancouver General Hospital, DSM-IV codes, American College, ACMG, OGM, LGG, Medical genetics, DRS, Research, Cancer, Medical device

Dr. Tara Spence from Vancouver General Hospital will present insights into her laboratory’s adoption of Stratys and its potential impact on hematological malignancy analysis

Key Points: 
  • Dr. Tara Spence from Vancouver General Hospital will present insights into her laboratory’s adoption of Stratys and its potential impact on hematological malignancy analysis
    A scientific platform presentation will feature Drs.
  • ACMG’s Annual Meeting brings together industry, medical, and academic professionals to discuss advances in clinical genetics research.
  • The ACMG conference will be held March 12-16, 2024, in Toronto, Canada.
  • All scientific posters will be presented in Exhibit Halls DE.

NMDP Awards 25th Annual ‘Amy Scholars’ Grant, Furthering Post-Transplant Research

Retrieved on: 
Wednesday, March 6, 2024
Bone marrow, Senior, Doctor of Philosophy, HCT, Research, Hematology, Graft-versus-host disease, Physician, Partnership, Data, University, Risk assessment, NMDP, Nursing, Patient, Disease, McGinn, DRS, Health equity, Laboratory, Buchbinder, Wilfrid Sellars, Pharmaceutical industry

Cieri and Sacirbegovic in their research efforts to improve the lives of those battling blood cancers and blood disorders.

Key Points: 
  • Cieri and Sacirbegovic in their research efforts to improve the lives of those battling blood cancers and blood disorders.
  • We are especially grateful to the Moore family, who generously funded the Amy Scholars Research Program in 2024,” said Joy King, Chief Advancement Officer, NMDP, and Executive Director, NMDP.
  • Since 1998, NMDP has invested more than $12 million, funding 51 early-career investigators and helping them develop research portfolios and establish their laboratories.
  • “For years, we have supported groundbreaking research by collaborating with an extensive network of physicians and scientists in impacting outcomes.